Supplementary Figures from METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zihao Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.22433522

2023-01-01

Abstract:This file describes supplementary figures.

What problem does this paper attempt to address?

Supplementary Materials from METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zihao Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.22433519.v1

2023-01-01

Abstract:This file describes supplementary methods and materials.
Supplementary Table S1 from METTL1-Mediated M7g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zhengde Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.22433516

2023-01-01

Abstract:This file shows the antibodies used in the study.
Supplementary Table S2 from METTL1-Mediated M7g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zhengde Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.22433513.v1

2023-01-01

Abstract:This table shows a list of primer and probe sequence used in our study.
METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zihao Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.CAN-22-0963

2023-01-04

Abstract:The tyrosine kinase inhibitor lenvatinib is a first-line drug for treating patients with advanced hepatocellular carcinoma (HCC). However, its efficacy is severely hampered by drug resistance. Insights into the molecular mechanisms underlying lenvatinib resistance could provide new strategies to improve and prolong responses. Here, we performed unbiased proteomic screening of parental and lenvatinib-resistant HCC cells and discovered that methyltransferase-like protein-1 (METTL1) and WD repeat domain 4 protein (WDR4), the two key components of the tRNA N7-methylguanosine (m7G) methyltransferase complex, were dramatically upregulated in lenvatinib-resistant cells. METTL1 knockdown overrode resistance by impairing the proliferation capacity of HCC cells and promoting apoptosis under lenvatinib treatment. In addition, overexpression of wild-type METTL1 but not its catalytic dead mutant induced lenvatinib resistance. Animal experiments including hydrodynamic injection, subcutaneous implantation, and orthotopic xenograft mouse models further demonstrated the critical function of METTL1/WDR4-mediated m7G tRNA modification in promoting lenvatinib resistance in vivo. Mechanistically, METTL1 promoted translation of EGFR pathway genes to trigger drug resistance. This work reveals the important role of METTL1-mediated m7G tRNA modification in promoting lenvatinib resistance and provides a promising prediction marker and intervention target for resistance. Significance: Upregulation of tRNA m7G methyltransferase complex components METTL1 and WDR4 promotes lenvatinib resistance in HCC and confers a sensitivity to METTL1 targeting, providing a promising strategy to override resistance.
Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Junying Zeng,Sharad Sharma,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22503690

2023-01-01

Abstract:PDF - 71K, Legends for Supplementary Figures 1 through 5.
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
METTL3-m6A-EGFR-axis Drives Lenvatinib Resistance in Hepatocellular Carcinoma.

Lina Wang,Qingxia Yang,Qianying Zhou,Fei Fang,Kai Lei,Ziqin Liu,Gaomin Zheng,Lefan Zhu,Jihui Huo,Xiaoxing Li,Sui Peng,Ming Kuang,Shuibin Lin,Manling Huang,Lixia Xu

DOI: https://doi.org/10.1016/j.canlet.2023.216122

IF: 9.756

2023-01-01

Cancer Letters

Abstract:Lenvatinib is emerging as the first-line therapeutic option for advanced hepatocellular carcinoma (HCC), but drug resistance remains a major hurdle for its long-term therapy efficiency in clinic. N6-methyladenosine (m6A) is the most abundant mRNA modification. Here, we aimed to investigate the modulatory effects and underlying mechanisms of m6A in lenvatinib resistance in HCC. Our data revealed that m6A mRNA modification was significantly upregulated in the HCC lenvatinib resistance (HCC-LR) cells compared to parental cells. Methyltransferase-like 3 (METTL3) was the most significantly upregulated protein among the m6A regulators. Either genetic or pharmacological inhibition of m6A methylation through METTL3 deactivation in primary resistant cell line MHCC97H and acquired resistant Huh7-LR cells decreased cell proliferation and increased cell apoptosis upon lenvatinib treatment in vitro and in vivo. In addition, the specific METTL3 inhibitor STM2457 improved tumor response to lenvatinib in multiple mouse HCC models, including subcutaneous, orthotopic and hydrodynamic models. The MeRIP-seq results showed that epidermal growth factor receptor (EGFR) was a downstream target of METTL3. EGFR overexpression abrogated the METTL3 knocked down-induced cell growth arrest upon lenvatinib treatment in HCC-LR cells. Thus, we concluded that targeting METTL3 using specific inhibitor STM2457 improved the sensitivity to lenvatinib in vitro and in vivo, indicating that METTL3 may be a potential therapeutic target to overcome lenvatinib resistance in HCC.
Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Lu Xu,Eiki Kikuchi,Chunxiao Xu,Hiromichi Ebi,Dalia Ercan,Katherine A. Cheng,Robert Padera,Jeffrey A. Engelman,Pasi A. Jänne,Geoffrey I. Shapiro,Takeshi Shimamura,Kwok-Kin Wong

DOI: https://doi.org/10.1158/0008-5472.22391819.v1

2023-01-01

Abstract:PDF file - 1.4MB, Supplemental Figure 1. MET is inducible in MET, TD/MET, and TL/MET models Supplemental Figure 2. Quantification of hMET expression in mouse models Supplemental Figure 3. Comparison of the tumor counts in mutant EGFR lung tumors with or without expression of hMET. Supplemental Figure 4. Representative MRI images prior to and after treatment in TL and TL/MET mice. Supplemental Figure 5. Xenografts of HCC827GR6 cells ectopically expressing EGFR E746_A750del/T790M are sensitive to the combination of WZ4002 and 17-DMAG. Supplemental Figure 6. The WZ4002/crizotinib or WZ4002/17-DMAG combinations suppress phosphorylation of EGFR, Akt, and Erk in TD and TD/MET to a greater extent than individual treatments
Supplementary Figure 3 from Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

Qingfeng Xiang,Weiqiang Chen,Meng Ren,Jingnan Wang,Hongwu Zhang,David Y.B. Deng,Lei Zhang,Changzhen Shang,Yajin Chen

DOI: https://doi.org/10.1158/1078-0432.22447926.v1

2023-01-01

Abstract:PDF file - 32K, Analysis of cyclin D1 expression and Apoptosis in HCC cells.
Supplementary Figure Legends and Table Legends from Targeting LUNX Inhibits Non–Small Cell Lung Cancer Growth and Metastasis

Xiaohu Zheng,Min Cheng,Binqing Fu,Xiaolei Fan,Qing Wang,Xiaoqing Yu,Rui Sun,Zhigang Tian,Haiming Wei

DOI: https://doi.org/10.1158/0008-5472.22407638.v1

2023-01-01

Abstract:Supplementary Figure Legends
Supplementary Figure 1 from C-Myc Alterations Confer Therapeutic Response and Acquired Resistance to C-Met Inhibitors in MET-Addicted Cancers

Aijun Shen,Lu Wang,Min Huang,Jingya Sun,Yi Chen,Yan-Yan Shen,Xinying Yang,Xin Wang,Jian Ding,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22405352

2023-01-01

Abstract:Supplementary Figure 1-Multiple kinases are co-activated in c-Met-resistant cells.
Figure S4 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

MinKe He,YeXing Huang,ZeFeng Du,ZhiCheng Lai,Hanyue Ouyang,JingXian Shen,DongSheng Wen,QiJiong Li,Yaojun Zhang,Wei,MinShan Chen,Li Xu,Anna Kan,Ming Shi

DOI: https://doi.org/10.1158/1078-0432.24826144

2023-01-01

Abstract:Representative images of patient three.
Figure S6 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

MinKe He,YeXing Huang,ZeFeng Du,ZhiCheng Lai,Hanyue Ouyang,JingXian Shen,DongSheng Wen,QiJiong Li,YaoJun Zhang,Wei,MinShan Chen,Li Xu,Anna Kan,Ming Shi

DOI: https://doi.org/10.1158/1078-0432.24826135

2023-01-01

Abstract:Representative images of patient five.
Figure S11 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

MinKe He,YeXing Huang,ZeFeng Du,ZhiCheng Lai,Hanyue Ouyang,JingXian Shen,DongSheng Wen,QiJiong Li,YaoJun Zhang,Wei,MinShan Chen,Li Xu,Anna Kan,Ming Shi

DOI: https://doi.org/10.1158/1078-0432.24826168.v1

2023-01-01

Abstract:Integration analysis of malignant hepatocytes.
Supplemental Figures and Tables from the HGF/c-MET Pathway is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

Tina Cascone,Xu Li,Heather Lin,Wenbin Liu,Hai T. Tran,Yuan Liu,Kathryn Howells,Vincent Haddad,Emer O. Hanrahan,Monique B. Nilsson,María Angélica Cortez,Uma Giri,Humam Kadara,Babita Saigal,Yun-Yong Park,Weiyi Peng,Ju-Seog Lee,Anderson J. Ryan,Juliane M. Jüergensmeier,Roy S. Herbst,Jing Wang,Robert R. Langley,Ignacio I. Wistuba,John Lee,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22468499.v1

2023-01-01

Abstract:Supplemental Figures and Tables
Supplementary Figures 1-5 from Mechanisms of &Lt;i>nt5c2-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia

Takaya Moriyama,Shuguang Liu,Jing Li,Julia Meyer,Xibin Zhao,Wentao Yang,Youming Shao,Richard J. Heath,Aleš Hnı́zda,William L. Carroll,Jun J. Yang

DOI: https://doi.org/10.1158/1535-7163.22510333.v1

2023-01-01

Abstract:Supplementary figure 1 and 2 describe protein purity and expression. Supplementary Figure 3 shows cell-based cytotoxic assays. Supplementary Figure 4 shows protein activity against several substrates. Supplementary Figure 5 describes levels of individual metabolites.
Supplementary Figure Legends 1-5 from Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

Seiji Yano,Wei Wang,Qi Li,Kunio Matsumoto,Haruko Sakurama,Takahiro Nakamura,Hirokazu Ogino,Soji Kakiuchi,Masaki Hanibuchi,Yasuhiko Nishioka,Hisanori Uehara,Tetsuya Mitsudomi,Yasushi Yatabe,Toshikazu Nakamura,Saburo Sone

DOI: https://doi.org/10.1158/0008-5472.22377138

2023-01-01

Abstract:Supplementary Figure Legends 1-5 from Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
Supplementary Figures and Figure Legends from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Tao Yu,Yingjun Zhao,Zhixiang Hu,Jing Li,Dandan Chu,Jiwei Zhang,Zhe Li,Bing Chen,Xiao Zhang,Hongyu Pan,Shengli Li,Hechun Lin,Lei Liu,Mingxia Yan,Xianghuo He,Ming Yao

DOI: https://doi.org/10.1158/0008-5472.22418432.v1

2023-01-01

Abstract:Supplementary Figures and Figure legends that contain the information of the characteristics of MetaLnc9 in NSCLC, Non-coding RNA analysis, the efficiency for MetaLnc9 overexpression and Knockdown, the molecular mechanism of PGK1 and NONO.
Figure S9 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

MinKe He,YeXing Huang,ZeFeng Du,ZhiCheng Lai,Hanyue Ouyang,JingXian Shen,DongSheng Wen,QiJiong Li,YaoJun Zhang,Wei,MinShan Chen,Li Xu,Anna Kan,Ming Shi

DOI: https://doi.org/10.1158/1078-0432.24826123

2023-01-01

Abstract:Representative images of patient eight.
Figure S5 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

MinKe He,YeXing Huang,ZeFeng Du,ZhiCheng Lai,Hanyue Ouyang,JingXian Shen,DongSheng Wen,QiJiong Li,Yaojun Zhang,Wei,MinShan Chen,Li Xu,Anna Kan,Ming Shi

DOI: https://doi.org/10.1158/1078-0432.24826141.v1

2023-01-01

Abstract:Representative images of patient four.

Supplementary Figures from METTL1-Mediated m<sup>7</sup>G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Supplementary Materials from METTL1-Mediated m<sup>7</sup>G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Supplementary Table S1 from METTL1-Mediated M<sup>7</sup>g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Supplementary Table S2 from METTL1-Mediated M<sup>7</sup>g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

METTL3-m6A-EGFR-axis Drives Lenvatinib Resistance in Hepatocellular Carcinoma.

Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Supplementary Figure 3 from Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

Supplementary Figure Legends and Table Legends from Targeting LUNX Inhibits Non–Small Cell Lung Cancer Growth and Metastasis

Supplementary Figure 1 from C-Myc Alterations Confer Therapeutic Response and Acquired Resistance to C-Met Inhibitors in MET-Addicted Cancers

Figure S4 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

Figure S6 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

Figure S11 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

Supplemental Figures and Tables from the HGF/c-MET Pathway is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

Supplementary Figures 1-5 from Mechanisms of &Lt;i>nt5c2</i>-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia

Supplementary Figure Legends 1-5 from Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

Supplementary Figures and Figure Legends from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Figure S9 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

Figure S5 from Lenvatinib, Toripalimab Plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)